Dyslipidaemia: Revealing the effect of CETP inhibition in cardiovascular disease

Nature Reviews Cardiology, Published online: 5 October 2017; doi:10.1038/nrcardio.2017.156

Initial randomized trials of cholesteryl ester transfer protein (CETP) inhibitors were terminated early owing to adverse effects or futility. The REVEAL trial now shows the benefit of CETP inhibition in coronary heart disease. Despite raising HDL-cholesterol levels, the cardiovascular effect of CETP inhibitors is probably due to lowering of non-HDL-cholesterol levels.

中文翻译：

---

血脂异常：揭示 CETP 抑制在心血管疾病中的作用

血脂异常：揭示 CETP 抑制在心血管疾病中的作用

Nature Reviews Cardiology，在线发表：2017 年 10 月 5 日；doi:10.1038/nrcardio.2017.156

最初的胆固醇酯转移蛋白 (CETP) 抑制剂随机试验因不良反应或无效而提前终止。REVEAL 试验现在显示了 CETP 抑制对冠心病的益处。尽管提高了 HDL-胆固醇水平，但 CETP 抑制剂的心血管作用可能是由于降低了非 HDL-胆固醇水平。